To our knowledge, we have for the first time reported the safety, antitumor activity, and pharmacokinetics of a novel anti-PD-1 inhibitor toripalimab in patients with heavily treated advanced NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.